191 related articles for article (PubMed ID: 8572663)
21. Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Ann Neurol; 1996 Jul; 40(1):99-107. PubMed ID: 8687199
[TBL] [Abstract][Full Text] [Related]
22. Selegiline slows the progression of the symptoms of Parkinson disease.
Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
[TBL] [Abstract][Full Text] [Related]
23. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
24. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.
Kieburtz K; McDermott M; Como P; Growdon J; Brady J; Carter J; Huber S; Kanigan B; Landow E; Rudolph A
Neurology; 1994 Sep; 44(9):1756-9. PubMed ID: 7936311
[TBL] [Abstract][Full Text] [Related]
25. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
[TBL] [Abstract][Full Text] [Related]
26. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
[TBL] [Abstract][Full Text] [Related]
27. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
Schneider E
J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
[TBL] [Abstract][Full Text] [Related]
28. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
29. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
30. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
31. R-(-)-deprenyl in the treatment of end-of-dose akinesia.
Ulm G; Fornadi F
J Neural Transm Suppl; 1987; 25():163-72. PubMed ID: 3123603
[TBL] [Abstract][Full Text] [Related]
32. L-deprenyl in the treatment of Parkinson's disease.
Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
LeWitt PA
J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
[TBL] [Abstract][Full Text] [Related]
35. Controversies in the therapy of Parkinson's disease.
Fahn S
Adv Neurol; 1996; 69():477-86. PubMed ID: 8615168
[TBL] [Abstract][Full Text] [Related]
36. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
37. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
38. Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
Head J; Ben-Shlomo Y; Lees AJ
Clin Neuropharmacol; 1998; 21(4):265-6. PubMed ID: 9704171
[No Abstract] [Full Text] [Related]
39. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Przuntek H; Kuhn W
J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
[TBL] [Abstract][Full Text] [Related]
40. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
